Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure

Hypertension

Volumn 58, Issue 6, 2011, Pages 1057-1065

  Xiao, Liang ^a   Gao, Lie ^a   Lazartigues, Eric ^b   Zucker, Irving H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin I (1 7); Angiotensin II; Angiotensin converting enzyme 2; Autonomic function; Baroreflex; Heart failure

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; NORADRENALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; MALE; MEAN ARTERIAL PRESSURE; MEDULLARY NUCLEUS; MOUSE; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPATHETIC NERVE; UPREGULATION; URINARY EXCRETION; WILD TYPE;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BAROREFLEX; ENZYME INDUCTION; HEART FAILURE; HUMANS; MALE; MEDULLA OBLONGATA; MICE; MICE, KNOCKOUT; MYOCARDIAL ISCHEMIA; NERVE TISSUE PROTEINS; NITRIC OXIDE; NOREPINEPHRINE; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT FUSION PROTEINS; REFLEX, ABNORMAL; SYMPATHETIC NERVOUS SYSTEM;

EID: 83155192160     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.176636     Document Type: Article

References (49)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
2. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
3. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
4. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD (P) H oxidase in RVLM. Am J Physiol Heart Circ Physiol. 2005;288: H2271-H2279.
5. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD (P) H oxidase. Circulation. 2005;112:1763-1770.
6. Liu D, Gao L, Roy SK, Cornish KG, Zucker IH. Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun. N-terminal kinase. Circ Res. 2006;99:1004-1011.
7. Kleiber AC, Zheng H, Sharma NM, Patel KP. Chronic AT1 receptor blockade normalizes NMDA-mediated changes in renal sympathetic nerve activity and NR1 expression within the PVN in rats with heart failure. Am J Physiol Heart Circ Physiol. 2010;298: H1546-H1555.
8. Zhu GQ, Patel KP, Zucker IH, Wang W. Microinjection of ANG II into paraventricular nucleus enhances cardiac sympathetic afferent reflex in rats. Am J Physiol Heart Circ Physiol. 2002;282: H2039-H2045.
9. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004;95:210-216.
10. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843.
11. Rowe BP, Saylor DL, Speth RC, Absher DR. Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regul Pept. 1995;56:139-146.
12. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de BI, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
13. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-528.
14. Sampaio WO, Henrique de CC, Santos RA, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007;50:1093-1098.
15. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA. Endothelial dysfunction and elevated blood pressure in MAS genedeleted mice. Hypertension. 2008;51:574-580.
16. Chappell MC, Brosnihan KB, Diz DI, Ferrario CM. Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides. J Biol Chem. 1989;264:16518-16523.
17. Potts PD, Horiuchi J, Coleman MJ, Dampney RA. The cardiovascular effects of angiotensin-(1-7) in the rostral and caudal ventrolateral medulla of the rabbit. Brain Res. 2000;877:58-64.
18. Fontes MA, Silva LC, Campagnole-Santos MJ, Khosla MC, Guertzenstein PG, Santos RA. Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors. Brain Res. 1994;665:175-180.
19. Silva LC, Fontes MA, Campagnole-Santos MJ, Khosla MC, Campos RR Jr, Guertzenstein PG, Santos RA. Cardiovascular effects produced by micro-injection of angiotensin-(1-7) on vasopressor and vasodepressor sites of the ventrolateral medulla. Brain Res. 1993;613:321-325.
20. Silva AQ, Santos RA, Fontes MA. Blockade of endogenous angiotensin-(1-7) in the hypothalamic paraventricular nucleus reduces renal sympathetic tone. Hypertension. 2005;46:341-348.
21. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30:535-541.
22. Gironacci MM, Valera MS, Yujnovsky I, Pena C. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension. 2004;44:783-787.
23. Yamazato M, Yamazato Y, Sun C, ez-Freire C, Raizada MK. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension. 2007;49:926-931.
24. Feng Y, Yue X, Xia H, Bindom SM, Hickman PJ, Filipeanu CM, Wu G, Lazartigues E. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res. 2008;102:729-736.
25. Feng Y, Xia H, Cai Y, Halabi CM, Becker LK, Santos RA, Speth RC, Sigmund CD, Lazartigues E. Brain-selective overexpression of human angiotensin- converting enzyme type 2 attenuates neurogenic hypertension. Circ Res. 2010;106:373-382.
26. Kar S, Gao L, Zucker IH. Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure. J Appl Physiol. 2010;108:923-932.
27. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995;269: H2147-H2154.
28. Butz GM, Davisson RL. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics. 2001;5:89-97.
29. Baudrie V, Laude D, Elghozi JL. Optimal frequency ranges for extracting information on cardiovascular autonomic control from the blood pressure and pulse interval spectrograms in mice. Am J Physiol Regul Integr Comp Physiol. 2007;292: R904-R912.
30. Stauss HM, Moffitt JA, Chapleau MW, Abboud FM, Johnson AK. Baroreceptor reflex sensitivity estimated by the sequence technique is reliable in rats. Am J Physiol Heart Circ Physiol. 2006;291: H482-H483.
31. Laude D, Baudrie V, Elghozi JL. Applicability of recent methods used to estimate spontaneous baroreflex sensitivity to resting mice. Am J Physiol Regul Integr Comp Physiol. 2008;294: R142-R150.
32. Ma X, Abboud FM, Chapleau MW. A novel effect of angiotensin on renal sympathetic nerve activity in mice. J Hypertens. 2001;19:609-618.
33. Kent BB, Drane JW, Blumenstein B, Manning JW. A mathematical model to assess changes in the baroreceptor reflex. Cardiology. 1972;57:295-310.
34. Gao L, Wang W, Liu D, Zucker IH. Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic heart failure. Circulation. 2007;115:3095-3102.
35. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press; 1997.
36. Infanger DW, Cao X, Butler SD, Burmeister MA, Zhou Y, Stupinski JA, Sharma RV, Davisson RL. Silencing nox4 in the paraventricular nucleus improves myocardial infarction-induced cardiac dysfunction by attenuating sympathoexcitation and periinfarct apoptosis. Circ Res. 2010;106:1763-1774.
37. Gao L, Wang WZ, Wang W, Zucker IH. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension. 2008;52:708-714.
38. Wang WZ, Gao L, Pan YX, Zucker IH, Wang W. AT1 receptors in the nucleus tractus solitarii mediate the interaction between the baroreflex and the cardiac sympathetic afferent reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol. 2007;292: R1137-R1145.
39. Yang RF, Yin JX, Li YL, Zimmerman MC, Schultz HD. Angiotensin-(1-7) increases neuronal potassium current via a nitric oxidedependent mechanism. Am J Physiol Cell Physiol. 2011;300: C58-C64.
40. Alzamora AC, Santos RA, Campagnole-Santos MJ. Hypotensive effect of ANG II and ANG-(1-7) at the caudal ventrolateral medulla involves different mechanisms. Am J Physiol Regul Integr Comp Physiol. 2002;283: R1187-R1195.
41. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49:185-192.
42. Wang Y, Patel KP, Cornish KG, Channon KM, Zucker IH. nNOS gene transfer to RVLM improves baroreflex function in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2003;285: H1660-H1667.
43. Hirooka Y, Shigematsu H, Kishi T, Kimura Y, Ueta Y, Takeshita A. Reduced nitric oxide synthase in the brainstem contributes to enhanced sympathetic drive in rats with heart failure. J Cardiovasc Pharmacol. 2003;42(suppl 1): S111-S115.
44. Li Y, Zhang W, Stern JE. Nitric oxide inhibits the firing activity of hypothalamic paraventricular neurons that innervate the medulla oblongata: role of GABA. Neuroscience. 2003;118:585-601.
45. Sakai K, Hirooka Y, Shigematsu H, Kishi T, Ito K, Shimokawa H, Takeshita A, Sunagawa K. Overexpression of eNOS in brain stem reduces enhanced sympathetic drive in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2005;289: H2159-H2166.
46. Saigusa T, Iriki M, Arita J. Brain angiotensin II tonically modulates sympathetic baroreflex in rabbit ventrolateral medulla. Am J Physiol. 1996;271: H1015-H1021.
47. Di Bona GF, Jones SY, Sawin LL. Effect of endogenous angiotensin II on renal nerve activity and its cardiac baroreflex regulation. J Am Soc Nephrol. 1998;9:1983-1989.
48. Lindley TE, Infanger DW, Rishniw M, Zhou Y, Doobay MF, Sharma RV, Davisson RL. Scavenging superoxide selectively in mouse forebrain is associated with improved cardiac function and survival following myocardial infarction. Am J Physiol Regul Integr Comp Physiol. 2009;296: R1-R8.
49. Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res. 2004;94:402-409.